Review explores GLP-1 Receptor Agonists' role in MASLD, connecting liver health to cardiovascular outcomes
GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes
Abstract
This review examines the therapeutic potential of GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), highlighting their impact on both liver and cardiovascular health.